DaVita (DVA) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Adjusted Operating Income: $586 million; Full Year Adjusted Operating Income: $2.094 billion.

Q4 Adjusted Earnings Per Share (EPS): $3.40; Full Year Adjusted EPS: $10.78.

Free Cash Flow: $309 million in Q4, totaling over $1 billion for the year.

U.S. Dialysis Treatments: Declined by 1.1% for the full year; Q4 saw a 20 basis point decline versus Q4 2024.

Revenue Per Treatment (RPT): Increased by approximately $12 sequentially in Q4, with a full-year increase of 4.7% to about $410.

2Strategic Updates and Business Highlights

Integrated Kidney Care (IKC): Achieved its first profitable year, slightly ahead of schedule, with a full-year adjusted operating income of $22 million. IKC patients showed significantly better clinical outcomes compared to the broader dialysis population.

Clinical Initiatives: Focus on vaccination rates, GLP-1 drug adoption, and new dialysis technologies aimed at improving patient outcomes and reducing hospitalizations.

Partnership with Elara Caring: A strategic investment of approximately $200 million to enhance home care services for patients with end-stage kidney disease (ESKD).

International Business: Generated $114 million in adjusted operating income, reflecting strong organic growth and successful integration of recent acquisitions.

3Forward Guidance and Outlook

2026 Adjusted Operating Income Guidance: Expected in the range of $2.085 billion to $2.235 billion (3.2% growth at midpoint).

Adjusted EPS Guidance for 2026: Projected between $13.60 and $15.00, indicating a 33% growth at the midpoint.

Free Cash Flow Guidance: Anticipated between $1 billion and $1.25 billion.

Treatment Volume Outlook: Expected to be flat compared to 2025, with a focus on improving clinical outcomes to drive future growth.

4Bad News, Challenges, or Points of Concern

Treatment Growth Pressure: Continued pressure on treatment growth due to elevated mortality rates and the expiration of enhanced premium tax credits, which is expected to create a $40 million headwind in 2026.

Patient Care Costs: Increased by approximately $6 sequentially in Q4, driven by seasonal health benefit costs and supply costs, with a full-year increase of 5.9%.

Cyber Incident Impact: The company faced challenges in 2025 due to a cyber incident, which affected operations and financial performance.

5Notable Q&A Insights

Volume Growth Confidence: CEO Javier Rodriguez emphasized that achieving over 2% volume growth hinges on improving mortality rates and implementing clinical initiatives, with expected benefits materializing over the next few years.

ACA Headwinds: The anticipated $40 million headwind from the expiration of enhanced premium tax credits is expected to be offset by the elimination of the cyber incident's financial impact.

IKC Performance Drivers: The outperformance in IKC was attributed to better shared savings and effective management of patient care, although future growth in this segment is expected to slow as the business matures.

Vaccination Rates: Current flu vaccination rates are at 80%, below the historical benchmark of over 90%, indicating room for improvement in patient care initiatives. Overall, DaVita's Q4 2025 results reflect a resilient business model with a focus on clinical excellence and strategic growth initiatives, despite facing headwinds in treatment growth and rising costs.